Isodiol International Inc. engages in the development, marketing, distribution, and sale of hemp-based consumer packaged goods and solutions in Canada and the United States. It develops and manufactures phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. The company offers pharmaceutical grade cannabinoid crystalline isolates derived from exempt parts of the hemp plant, as well as micro-encapsulations and nanotechnology for consumable and topical skin care products. It is also involved in manufacturing and distributing hemp oil and nicotine e-liquids, as well as personal care products; provision of apparel and merchandising solutions; manufactures and sells hemp infused beverages; and supplies pharmaceutical products. The company is headquartered in Vancouver, Canada.

Isodiol International Inc.

Isodiol produces CBD products made from non-GMO hemp, ensuring that each batch is third-party tested and free of pesticides and heavy metals. Isodiol's offerings include products that are THC-free and manufactured in compliance with the 2018 Farm Bill.

Isodiol

Isodiol International, Inc | 1,357 followers on LinkedIn. Live Healthier, Naturally | Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of consumer products.

We have pioneered many firsts for the cannabis industry, including commercialization of 99%+ pure, pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products and most recently received approval as having the first CBD designated as an Active Pharmaceutical Ingredient as was announced April 26, 2018.

Our growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding our phytoceutical portfolio and we will continue to aggressively expand internationally into Latin America, Asia and Europe.

Commercial Operations - Isodiol International, Inc

Fernando Blanco Armendáriz

	Mar '19
account payables	4.14M -
accumulated other comprehensive income loss	4.31M -
cash and cash equivalents	302.27K -
cash and short term investments	2.15M -
common stock	132.47M -
deferred revenue	1.77M -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory	642.72K -
long term debt	3.88M -
long term investments	1.62M -
net debt	5.76M -
net receivables	10.41M -
other assets	1 -
other current assets	1.65M -
other current liabilities	513.35K -
other liabilities	1 -
other non current assets
other non current liabilities
othertotal stockholders equity	1 -
preferred stock
property plant equipment net	1.21M -
retained earnings	-131.60M -
short term debt	2.18M -
short term investments	1.85M -
tax assets
tax payables
total assets	17.68M -
total current assets	14.85M -
total current liabilities	8.60M -
total debt	6.06M -
total investments	3.47M -
total liabilities	12.49M -
total liabilities and stockholders equity	17.68M -
total non current assets	2.83M -
total non current liabilities	3.88M -
total stockholders equity	5.19M -

ISOL

COM:ISODIOL

Isodiol

Market Cap

135.44K

Beta: -

Volume Today

500

Avg: -

Preview